IM Cannabis Signs Non-Binding LOI to Acquire 51% of Space Defense Innovations
IMCC has more than doubled off its 52-week low of $1.55 on elevated volume (12× avg).
Summary
IM Cannabis signed a non-binding LOI to acquire 51% of Space Defense Innovations, a Polish UAS distributor, marking a strategic pivot into defense technology amid ongoing financial distress.
Key Events · M&A and Partnerships · IMCC
-
Non-Binding LOI for 51% of SDI
IM Cannabis entered a non-binding Letter of Intent to acquire 51% of Space Defense Innovations LLC, a Polish UAS distributor, on a fully diluted basis.
-
Complex Consideration Structure
Consideration includes IMCC common shares capped at 19.99% beneficial ownership per SDI shareholder, pre-funded warrants, a 24-month seller loan at 9% annual interest with 100% warrant coverage exercisable at a 25% premium to the closing price, and a five-year call option on the remaining 49%.
-
EUR 2.3M Convertible Credit Line
IMCC will provide SDI at closing with an on-demand line of credit of up to EUR 2.3 million (36-month maturity), convertible at IMCC's discretion into SDI shares at the fair-market valuation established at closing, subject to a minimum company valuation of US$5 million.
-
Strategic Pivot into Defense Tech
The transaction aligns with IMCC's stated objective of building technology-driven businesses beyond its core medical cannabis operations in Israel and Germany, with SDI holding exclusivity in Poland for BlueBird Aero Systems' tactical UAS products.
Analysis · IMCC · Life Sciences
IM Cannabis is pivoting beyond medical cannabis into European tactical UAS distribution via a non-binding LOI for 51% of Space Defense Innovations. The deal structure is complex: share consideration capped at 19.99% per SDI shareholder, pre-funded warrants, a 24-month seller loan at 9% interest with 100% warrant coverage, a five-year call option on the remaining 49%, and a EUR 2.3 million convertible credit line. This comes against a backdrop of going-concern doubts, Nasdaq delisting risk, and repeated dilutive convertible note financings — the company is betting on a defense-tech pivot while its core cannabis business struggles. The LOI is non-binding and subject to due diligence, definitive agreements, and regulatory approvals, so completion is far from assured.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $10.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $1.55 to $77.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.